Disease · MONDO_0010030
Comparisons in its trials22
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 22
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Arm 1: Iscalimab 600 mg vs Arm 2 - Iscalimab 300 mg: Incidence of Anti-iscalimab Antibodies in Plasma | 1 of 152 | 2 of 54 | 206 | NCT04541589 | Trial comparisons |
| Arm 1: Iscalimab 600 mg vs Arm 2 - Iscalimab 300 mg: deaths from any cause | 0 of 152 | 0 of 54 | 206 | NCT04541589 | Trial comparisons |
| Arm 1: Iscalimab 600 mg vs Arm 2 - Iscalimab 300 mg: serious adverse events | 13 of 152 | 2 of 54 | 206 | NCT04541589 | Trial comparisons |
| Population 2: VIB4920 vs Population 2: Placebo: Population 2: Number of Participants Who Achieved ESSPRI Response at Day 169 | 36 of 54 | 18 of 55 | 109 | NCT04129164 | Trial comparisons |
| SAR441344 vs Placebo: deaths from any cause | 0 of 42 | 0 of 42 | 84 | NCT04572841 | Trial comparisons |
| SAR441344 vs Placebo: serious adverse events | 1 of 42 | 1 of 42 | 84 | NCT04572841 | Trial comparisons |
| Baminercept 100 mg vs Placebo: serious adverse events | 5 of 33 | 1 of 19 | 52 | NCT01552681 | Trial comparisons |
| DNase vs Vehicle: deaths from any cause | 0 of 25 | 0 of 22 | 47 | NCT02193490 | Trial comparisons |
| DNase vs Vehicle: serious adverse events | 0 of 25 | 0 of 22 | 47 | NCT02193490 | Trial comparisons |
| Any MEDI5872 210 mg vs Placebo: Number of Participants With Adverse Events of Special Interest (AESIs) | 6 of 31 | 1 of 16 | 47 | NCT02334306 | Trial comparisons |
| Any MEDI5872 210 mg vs Placebo: deaths from any cause | 0 of 31 | 0 of 16 | 47 | NCT02334306 | Trial comparisons |
| Any MEDI5872 210 mg vs Placebo: serious adverse events | 1 of 31 | 0 of 16 | 47 | NCT02334306 | Trial comparisons |
| Efgartigimod vs Placebo: deaths from any cause | 0 of 23 | 0 of 11 | 34 | NCT05817669 | Trial comparisons |
| Efgartigimod vs Placebo: serious adverse events | 1 of 23 | 0 of 11 | 34 | NCT05817669 | Trial comparisons |
| CDZ173 vs Placebo: deaths from any cause | 0 of 20 | 0 of 10 | 30 | NCT02775916 | Trial comparisons |
| CDZ173 vs Placebo: serious adverse events | 1 of 20 | 0 of 10 | 30 | NCT02775916 | Trial comparisons |
| Efgartigimod-Efgartigimod vs Placebo-Efgartigimod: Number of Participants With ADA Against Efgartigimod Over the 48-week Treatment Period | 6 of 17 | 4 of 7 | 24 | NCT06203457 | Trial comparisons |
| Efgartigimod-Efgartigimod vs Placebo-Efgartigimod: deaths from any cause | 0 of 17 | 0 of 7 | 24 | NCT06203457 | Trial comparisons |
| Efgartigimod-Efgartigimod vs Placebo-Efgartigimod: serious adverse events | 0 of 17 | 2 of 7 | 24 | NCT06203457 | Trial comparisons |
| Raptiva vs Placebo: serious adverse events | 0 of 8 | 0 of 3 | 11 | NCT00344448 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0010030/comparisons